Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY3389934 and Aspirin Interaction Study in Healthy Participants
NCT07652723Phase 1Recruiting
- Sponsor
- Bayer
- Start
- May 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BAY3389934 in sepsis (6 arms), sponsored by Bayer. Primary endpoint: Treatment-Emergent Adverse Events. Started May 2026; status: recruiting.
02
Drugs
BAY3389934
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07652723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652723.